 Heparin
"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
| Descriptor ID |
D006493
|
| MeSH Number(s) |
D09.698.373.400
|
| Concept/Terms |
Heparin- Heparin
- Unfractionated Heparin
- Heparin, Unfractionated
- Heparinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Heparin".
Below are MeSH descriptors whose meaning is more specific than "Heparin".
This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 1 | 4 | | 1994 | 3 | 5 | 8 | | 1995 | 2 | 0 | 2 | | 1996 | 0 | 1 | 1 | | 1997 | 1 | 5 | 6 | | 1998 | 3 | 3 | 6 | | 2000 | 2 | 3 | 5 | | 2001 | 2 | 3 | 5 | | 2002 | 4 | 3 | 7 | | 2003 | 3 | 2 | 5 | | 2004 | 1 | 3 | 4 | | 2005 | 5 | 3 | 8 | | 2006 | 1 | 3 | 4 | | 2007 | 1 | 1 | 2 | | 2008 | 2 | 2 | 4 | | 2009 | 0 | 3 | 3 | | 2010 | 6 | 2 | 8 | | 2011 | 7 | 1 | 8 | | 2012 | 4 | 0 | 4 | | 2013 | 3 | 5 | 8 | | 2014 | 4 | 5 | 9 | | 2015 | 2 | 3 | 5 | | 2016 | 2 | 2 | 4 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 1 | 2 | | 2019 | 3 | 3 | 6 | | 2020 | 5 | 1 | 6 | | 2021 | 4 | 2 | 6 | | 2022 | 0 | 5 | 5 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Heparin" by people in Profiles.
-
Stettler GR, Sumislawski JJ, Debot M, Moore EE, Burlew CC. Low-Dose Heparin Infusion as Venous Thromboembolism Chemoprophylaxis in Patients With Blunt Cerebrovascular Injury. J Surg Res. 2023 06; 286:1-7.
-
Kanack AJ, Jones CG, Singh B, Leger RR, Splinter NP, Heikal NM, Pruthi RK, Chen D, George G, Abou-Ismail MY, Wool GD, Gundabolu K, Padmanabhan A. Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies. Blood. 2022 12 22; 140(25):2722-2729.
-
Thomas KA, Shea SM, Saini A, Muszynski JA, Spinella PC. Correlation between Thrombin Generation, Standard Coagulation Assays, and Viscoelastic Assays for Hemostatic Assessment in Critically Ill Children. J Appl Lab Med. 2022 09 01; 7(5):1108-1119.
-
McDonald R, Kuhn K, Nguyen TB, Tannous A, Schauer I, Santoro N, Bradford AP. A randomized clinical trial demonstrating cell type specific effects of hyperlipidemia and hyperinsulinemia on pituitary function. PLoS One. 2022; 17(5):e0268323.
-
Kanack AJ, Singh B, George G, Gundabolu K, Koepsell SA, Abou-Ismail MY, Moser KA, Smock KJ, Green D, Major A, Chan CW, Wool GD, Reding M, Ashrani AA, Bayas A, Grill DE, Padmanabhan A. Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol. 2022 05; 97(5):519-526.
-
Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J. 2022 04; 246:136-143.
-
Vigneshwar NG, Moore HB, Moore EE. Challenges in acute care surgery: Zone II neck gunshot wound at a remote rural hospital. J Trauma Acute Care Surg. 2021 12 01; 91(6):e152-e154.
-
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 12 01; 181(12):1612-1620.
-
Swayngim R, Preslaski C, Burlew CC, Beyer J. Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis. Thromb Res. 2021 Dec; 208:18-25.
-
Nicolai L, Adornetto R, Bianchini R, Carrer F, Borgo CD, Doro S, Masotti D, Puglisi C, Turini L, Wohlauer M, Galeazzi E. Distal arteriovenous fistula to preserve patency in COVID-19-associated acute limb ischemia. Semin Vasc Surg. 2021 Sep; 34(3):96-100.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|